Holistic Orphan Disease Commercialisation Strategy

Are you planning to commercialise an orphan drug in the UK or Europe?

The Healthonauts are an experienced partner for holistic orphan disease strategies, supporting you from early market assessment through to launch planning and execution.

Commercialising orphan drugs presents unique challenges for biotech companies — from small patient populations and complex stakeholder landscapes to pricing, access and evidence generation. Success requires innovative, well-sequenced strategies that enable timely access for the right patients.

Our team brings many years of rare disease commercialisation experience, supporting the development and implementation of holistic, science-led and patient-centric strategies. We combine deep understanding of mode of action, technology, indication and patient populations with insight into the regulatory, access and market environment.

We work closely with leadership teams to design strategies that fit your organisation, your resources and your ambition — always with patient benefit at the centre. Through rigorous analysis, due diligence, risk assessment and forecasting, we place your strategy on a robust data foundation and support operational delivery through to launch.

Where required, we provide experienced interim managers across key functions, ensuring continuity, pace and execution during critical phases.

Proven rare disease experience

David Lewis, Carsten von Blohn and Natalie Koster have supported the development and launch of numerous orphan and rare disease therapies in operational, strategic and advisory roles. Experience spans haemophilia, HAE, PH1, AHP, APDS, cystic fibrosis, osteogenesis imperfecta, Bardet-Biedl syndrome, Leber’s congenital amaurosis, hATTR, and multiple rare oncology and haematology indications.

Holistic orphan disease strategy services

• Strategic consulting and planning

• Indication and patient population analysis

• Scientific due diligence

• Market and competitive analysis

• Forecasting and financial modelling

• Operational implementation

• Placement of interim managers